Claims for Patent: 5,925,549

Summary for Patent: 5,925,549

Title:	Soluble 7-transmembrane domain G-protein-coupled receptor compositions and methods
Abstract:	Chimeric polypeptides containing the N-terminal amino acid sequence of a glycoprotein hormone receptor polypeptide and a membrane anchor polypeptide, with a protease recognition site between the two, are disclosed. Also disclosed are nucleic acids encoding such polypeptides, expression vectors containing such nucleic acids and methods of producing such recombinant chimeric polypeptides, as well as uses thereof. The chimeric polypeptides are particularly useful for the production of soluble glycoprotein hormone receptor polypeptides.
Inventor(s):	Hsueh; Aaron J. W. (Stanford, CA), Kobilka; Brian K. (Palo Alto, CA), Kudo; Masataka (Menlo Park, CA)
Assignee:	The Board of Trustees of the Leland Stanford Junior University (Stanford, CA)
Application Number:	08/837,151
Patent Claims:	1. A nucleic acid encoding a chimeric polypeptide, comprising the first extracellular domain of a G-protein coupled receptor, wherein said first extracellular domain defines the ligand binding domain of said G-protein coupled receptor, a membrane anchor polypeptide joined at its amino terminus to the carboxyl terminus of said first extracellular domain, wherein said membrane anchor polypeptide is not naturally found in a G-protein coupled receptor, and a protease recognition site interposed between said first extracelluar domain and said membrane anchor polypeptide, wherein said protease recognition site is not present in said first extracelluar domain. 2. The nucleic acid of claim 1, wherein said protease recognition site is a thrombin recognition site. 3. The nucleic acid of claim 1, wherein said G-protein coupled receptor is a luteinizing hormone receptor. 4. The nucleic acid of claim 1, wherein said G-protein coupled receptor is a follicle stimulating hormone receptor. 5. The nucleic acid of claim 1, wherein said G-protein coupled receptor is a thyroid stimulating hormone receptor. 6. The nucleic acid of claim 1, wherein said membrane anchor polypeptide is the transmembrane portion of a CD8 molecule. 7. An expression vector comprising (a) the nucleic acid of claim 1; and (b) regulatory sequences effective to express said nucleic acid in a host cell. 8. The vector of claim 7, wherein the protease recognition site is a thrombin recognition site. 9. The vector of claim 7, wherein the membrane anchor polypeptide is the transmembrane portion of a CD8 molecule. 10. The vector of claim 7, wherein the G-protein coupled receptor is selected from the group consisting of a luteinizing hormone receptor, a follicle stimulating hormone receptor, a thyroid stimulating hormone receptor, a calcitonin receptor, a glucagon receptor, a glucagon-like peptide 1 receptor, a metabotropic glutamate receptor, a parathyroid hormone receptor, a vasoactive intestinal peptide receptor, a secretin receptor, and a growth hormone releasing factor receptor. 11. A method of recombinantly producing a chimeric polypeptide containing the first extracellular domain of a G-protein coupled receptor, wherein said first extracellular domain defines the ligand binding domain of said G-protein coupled receptor, comprising introducing into selected host cells, an expression vector of claim 7, where the regulatory sequences of the vector are effective to express said nucleic acid in said host cells, and culturing said host cells under conditions resulting in the expression of the nucleic acid. 12. The method of claim 11, which further includes incubating said host cells in the presence of a protease which recognizes said protease recognition site, to cleave said first extracellular domain from the remainder of said chimeric protein. molecule. 13. A host cell transfected with a vector of claim 7. 14. The nucleic acid of claim 1, wherein said G-protein coupled receptor is a calcitonin receptor. 15. The nucleic acid of claim 1, wherein said G-protein coupled receptor is a glucagon receptor. 16. The nucleic acid of claim 1, wherein said G-protein coupled receptor is a glucagon-like peptide 1 (GLP-1) receptor. 17. The nucleic acid of claim 1, wherein said G-protein coupled receptor is a metabotropic glutamate receptor. 18. The nucleic acid of claim 1, wherein said G-protein coupled receptor is a parathyroid hormone (PTH) receptor. 19. The nucleic acid of claim 1, wherein said G-protein coupled receptor is a vasoactive intestinal peptide (VIP) receptor. 20. The nucleic acid of claim 1, wherein said G-protein coupled receptor is a secretin receptor. 21. The nucleic acid of claim 1, wherein said G-protein coupled receptor is a growth hormone releasing factor (GRF) receptor. 22. The nucleic acid of claim 1, wherein said G-protein coupled receptor is a human G-protein coupled receptor. 23. A chimeric polypeptide comprising the first extracellular domain of a G-protein coupled receptor, wherein said first extracellular domain defines the ligand binding domain of said G-protein coupled receptor, a membrane anchor polypeptide joined at its amino terminus to the carboxyl terminus of said first extracellular domain, wherein said membrane anchor polypeptide is not naturally found in a G-protein coupled receptor, and a protease recognition site interposed between said first extracelluar domain and said membrane anchor polypeptide, wherein said protease recognition site is not present in said first extracelluar domain. 24. The polypeptide of claim 3, wherein said protease recognition site is a thrombin recognition site. 25. The polypeptide of claim 23, wherein said G-protein coupled receptor is a luteinizing hormone receptor. 26. The polypeptide of claim 23, wherein said G-protein coupled receptor is a follicle stimulating hormone receptor. 27. The polypeptide of claim 23, wherein said G-protein coupled receptor is a thyroid stimulating hormone receptor. 28. The polypeptide of claim 23, wherein said membrane anchor polypeptide is the transmembrane portion of a CD8 molecule. 29. The polypeptide of claim 23, wherein said G-protein coupled receptor is a calcitonin receptor. 30. The polypeptide of claim 23, wherein said G-protein coupled receptor is a glucagon receptor. 31. The polypeptide of claim 23, wherein said G-protein coupled receptor is a glucagon-like peptide 1 (GLP-1) receptor. 32. The polypeptide of claim 23, wherein said G-protein coupled receptor is a metabotropic glutamate receptor. 33. The polypeptide of claim 23, wherein said G-protein coupled receptor is a parathyroid hormone (PTH) receptor. 34. The polypeptide of claim 23, wherein said G-protein coupled receptor is a vasoactive intestinal peptide (VIP) receptor. 35. The polypeptide of claim 23, wherein said G-protein-coupled receptor is a secretin receptor. 36. The polypeptide of claim 23, wherein said G-protein coupled receptor is a growth hormone releasing factor (GRF) receptor. 37. The polypeptide of claim 23, wherein said G-protein coupled receptor is a human G-protein coupled receptor.

Details for Patent 5,925,549

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2016-04-15